Results 91 to 100 of about 18,139 (185)

Real‐World Pharmacological Management of Alcohol Dependence in a Nepalese Rehabilitation Center: Prospective Cohort Study

Public Health Challenges, Volume 5, Issue 1, March 2026.
This prospective cohort study demonstrates that structured, evidence‐informed pharmacological management significantly reduced alcohol withdrawal severity and improved liver enzyme profiles among alcohol dependence patients in a Nepalese rehabilitation center, supporting the implementation of standardized treatment protocols in resource‐limited ...
Sanjay Singh, Nirmal Raj Marasine, Sabina Sankhi, Kabita Bhandari, Gajendra Bahadur Bhuju   +4 more
wiley   +1 more source

G9a inhibition reduces stress‐potentiated alcohol drinking in both male and female mice: Implications for safe and effective pharmacological therapeutics for alcohol use disorder

Alcohol, Clinical and Experimental Research, Volume 50, Issue 3, March 2026.
Targeting stress‐escalated alcohol drinking could help patients with alcohol use disorder (AUD). We found that reducing the activity of the epigenetic regulatory enzyme G9a (aka euchromatic histone‐lysine N‐methyltransferase 2 or EHMT2) by repeated systemic administration of a G9a inhibitor reduces stress‐escalated ethanol drinking in a mouse model ...
Deltrice Holmes, Marcelo F. Lopez, Howard C. Becker, Christopher W. Cowan, Ethan M. Anderson   +4 more
wiley   +1 more source

Socio‐economic differences in the effectiveness of pharmacotherapy use in alcohol use disorder: A cohort study of 148 626 individuals in Sweden

Addiction, Volume 121, Issue 3, Page 597-605, March 2026.
Abstract Aim To examine the socioeconomic differences in the effectiveness of alcohol use disorders (AUD) pharmacotherapy and risk of AUD hospitalisation. Design A prospective register‐based cohort study. Setting Sweden. Participants Individuals who were registered as living in Sweden in 2005 (16–64 years) with a first‐time AUD diagnosis and complete ...
Devy L. Elling, Emelie Thern, Lluís Mangot‐Sala, Jari Tiihonen, Anders Hammarberg, Daniel Falkstedt, Heidi Taipale   +6 more
wiley   +1 more source

RATIONALE FOR THE SELECTION OF AUXILIARY COMPONENTS FOR THE NALTREXONE HYDROCHLORIDE NASAL SPRAY

Разработка и регистрация лекарственных средств, 2019
The work is devoted to the development of nasal spray containing naltrexone hydrochloride. Naltrexone in doses of 3-5 mg/day acts on the opioid growth factor receptor (OGFr) and toll-like receptor 4 that makes it promising for use in the complex therapy ...
Y. M. Domnina, S. A. Kedik, V. V. Suslov, E. A. Shnyak   +3 more
doaj  

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)

Diabetes, Obesity and Metabolism, Volume 28, Issue 3, Page 2403-2415, March 2026.
Abstract Aims To assess the real‐world effectiveness of semaglutide versus tirzepatide in reducing major adverse cardiovascular events (MACE) among patients with overweight/obesity and established atherosclerotic cardiovascular disease (ASCVD) without diabetes in an insured US population.
Lauren Wilson, Zhenxiang Zhao, Victoria Divino, Matthew Bassan, Bríain Ó. Hartaigh, Signe Stensen, Kerem Ozer   +6 more
wiley   +1 more source

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines

Physiological Reports
The aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone
Robert L. Joyner, Joseph A. Hollenbaugh, Donald D'Aquila, Marc Fishman, Steven M. Cohen, Veera Holdai, Jeffrey D. Benner   +6 more
doaj   +1 more source

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

Patient Preference and Adherence, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
doaj  

Managing the Complex Intersection Between Substance Use Disorders and Infectious Diseases

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY, Volume 9, Issue 3, March 2026.
Karissa Chow, Amanda Binkley, Jessica Meisner, Samantha Huo, Matthew Hinton   +4 more
wiley   +1 more source

Naltrexone treatment improves anxiety- and depression-like behavior in alcohol-exposed mice. [PDF]

Behav Pharmacol
Yang S, Tong L, Zhang L, Cui R, Lyu X, He L, Liu H.   +6 more
europepmc   +1 more source

Increased activation of ErbB and NF‐κB signalling pathways in Darier disease affected skin

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 3, Page 506-509, March 2026.
Nancy Ernst, Ralf J. Ludwig, Artem Vorobyev   +2 more
wiley   +1 more source